Intellia Therapeutics stock jumped 6.2% to US$11.94 after earnings, which suggests investors heard something they liked from a gene editing story that has delivered sharp volatility in recent months. The headline is simple: the science stepped forward while the income statement stayed firmly in loss-making territory.

Q2 revenue came in at US$7.7m and Intellia reported a net loss of US$106.6m. The cash pile of US$628.4m and management’s stated runway into at least 2028 now sit at the center of the Intellia Therapeutics investment debate.

Love the potential of Intellia Therapeutics but concerned about ongoing losses and cash burn risk? You may want to take a look at our screener of profitable companies with stronger balance sheets in the list of solid balance sheet and fundamentals stocks (49 results).

Q2 2026 Earnings Summary

• Revenue, Q2 2026 vs Q2 2025: US$7.66m vs US$14.25m (revenue declined 46%)
• Net Loss, Q2 2026 vs Q2 2025: US$106.63m loss vs US$101.26m loss (loss widened 5%)
• Basic EPS, Q2 2026 vs Q2 2025: US$0.80 loss per share vs US$0.98 loss per share (loss per share narrowed 18%)
• Trailing 12 Month Basic EPS, Q2 2026 vs Q2 2025: US$3.34 loss per share vs US$4.68 loss per share (loss per share narrowed 29%)

Prefer clear visuals instead of scrolling through more earnings tables and cash flow figures? See how Intellia Therapeutics looks on one clean dashboard that pulls together its company report for Intellia Therapeutics.

Intellia bullish story leans on de-risked pipeline

The bullish angle on Intellia Therapeutics centers on a de-risked in vivo gene editing platform moving toward its first commercial opportunity. The Q2 print supports that direction. Lonvo-z has completed a successful Phase 3 with strong efficacy and clean safety, and a rolling BLA is underway with a 2027 US launch target. Nex-z Phase 3 trials have resumed after prior holds, and enrollment is progressing. Losses remain, yet the loss per share has narrowed year on year and the share price rose 6.2% after earnings, which signals constructive sentiment.

Bearish concerns still focus on cash burn and execution

The bearish story around Intellia Therapeutics is not dismissed by this quarter. Revenue of US$7.7m declined 46% year on year as collaboration income softened, while the Q2 net loss widened to US$106.6m. The company remains reliant on external funding, highlighted by the April equity raise and high short interest reported in July. A US$628.4m cash balance and runway into at least 2028 ease near term liquidity concerns, but commercialization, regulatory decisions and long trial timelines keep execution risk and potential future dilution firmly on the table.

After a sharp move in Intellia Therapeutics stock and fresh dilution, are these pressures contained or part of deeper structural issues? Review our risk analysis for Intellia Therapeutics which shows 3 important warning signs

Stay Ahead With Simply Wall St

After a volatile few months and a fresh look at Intellia Therapeutics earnings, it can help to track the stock closely before committing new capital. Register for free with Simply Wall St and add Intellia Therapeutics to your Watchlist so you can monitor its share price against fair value and watch how the story develops. Once you have a position, keep on top of the most important news, valuation updates and risk flags through your personalized Portfolio Command Center that filters out background noise. For a longer term view, tap into crowd insights and different theses inside the Community so you can spot potential catalysts and risks early and stay a step ahead of the market.

Seeking Alternatives Beyond Intellia Therapeutics

Fresh opportunities rarely stay quiet for long. Some stocks build breakout momentum while they are still under the radar for now. Check these ideas before the crowd, and consider acting while they are still less widely followed.

• Spot stronger balance sheets before they start attracting wider attention by scanning a curated list of solid balance sheet and fundamentals stocks (49 results) that focuses on resilient cash flows and cleaner fundamentals.
• Identify potential leaders related to AI earlier in their development by reviewing hand picked 68 profitable AI stocks that aren't just burning cash that already generate real profits instead of just burning cash.
• Focus on resilient businesses with steadier share price behavior using a refined set of 78 resilient stocks with low risk scores that can help keep overall portfolio risk in tighter control.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.